current
ebola
viru
ebov
crisi
demonstr
global
prepar
respond
therapeut
treat
exist
infect
act
prophylact
food
drug
administr
fda
european
medicin
agenc
emea
approv
therapeut
importantli
suggest
prepar
pathogen
known
nearli
forti
year
current
ebov
outbreak
alreadi
prove
remark
costli
term
mortal
financi
ramif
best
approach
ebov
far
reli
public
health
measur
contain
use
past
outbreak
lesson
ebov
undoubtedli
import
next
viru
outbreak
also
rais
mani
question
point
littl
know
virus
gener
well
best
share
knowledg
openli
rel
small
number
studi
attempt
identifi
compound
activ
ebov
two
recent
studi
util
highthroughput
screen
subset
fda
approv
drug
differ
ebov
strain
zair
sudan
vitro
vivo
independ
report
suggest
promis
antimalari
amodiaquin
chloroquin
one
studi
select
estrogen
receptor
modul
serm
clomiphen
toremifen
activ
anoth
chloroquin
date
progress
beyond
mous
ebov
model
use
studi
hypothes
could
use
four
molecul
comput
defin
featur
import
activ
previou
studi
exhaust
screen
fda
drug
taken
opportun
suggest
addit
compound
look
anoth
perspect
nonantivir
drug
may
worth
follow
even
though
molecular
mechan
unknown
compound
may
broad
antivir
activ
report
describ
modest
inhibitori
activ
virus
sever
studi
identifi
nonfda
approv
drug
includ
silico
dock
approach
identifi
molecul
target
viral
interfac
molecul
similar
fda
benzimidazol
aminoquinolin
compound
activ
ebov
anoth
good
exampl
recent
silico
dock
million
druglik
compound
dock
viral
protein
protein
identifi
multipl
pyrrolidinon
inhibit
polymeras
cofactor
activ
pyrrolidinon
bind
alpha
helix
propos
import
viral
function
limit
knowledg
small
molecul
potenti
target
studi
whether
fdaapprov
drug
activ
vitro
vivo
versu
ebov
could
target
two
paper
describ
compound
activ
inhibitor
differ
ebov
strain
vitro
vivo
name
amodiaquin
chloroquin
one
studi
clomiphen
toremifen
anoth
activ
molecul
use
vitro
vivo
activ
build
common
featur
pharmacophor
discoveri
studio
biovia
san
diego
ca
conform
molecul
gener
caesar
algorithm
identifi
key
featur
pharmacophor
use
search
variou
databas
molecul
conform
fast
conform
gener
method
maximum
energi
threshold
kcalmol
creat
pharmacophor
use
search
microsourc
spectrum
databas
http
wwwmsdiscoverycomspectrumhtml
well
cdd
fda
drug
dataset
http
wwwcollaborativedrugcompagespublicaccess
case
hit
retriev
initi
van
der
waal
surfac
amodiaquin
potent
chloroquin
ad
limit
number
hit
retriev
receptorligand
pharmacophor
protein
gener
crystal
structur
protein
data
bank
pdb
pharmacophor
construct
use
receptorligand
pharmacophor
gener
protocol
discoveri
studio
version
biovia
san
diego
ca
maximum
number
pharmacophor
minimum
featur
maximum
number
featur
describ
elsewher
pdb
use
dock
use
libdock
discoveri
studio
biovia
san
diego
ca
propos
bind
site
center
ligand
site
sphere
creat
coordin
diamet
protocol
includ
hotspot
dock
toler
fast
conform
method
also
use
along
steepest
descent
minim
charmm
paramet
follow
default
set
ligand
remov
bind
site
redock
four
fda
approv
drug
activ
ebola
dock
structur
sdf
file
molecul
visual
alongsid
origin
ligand
interact
plot
gener
pharmacophor
gener
use
vivo
vitro
activ
amodiaquin
chloroquin
clomiphen
toremifen
supplement
tabl
repres
relev
fda
approv
drug
date
pharmacophor
consist
hydrophob
featur
hydrogen
bond
acceptor
featur
figur
pharmacophor
van
der
waal
surfac
also
use
search
fda
drug
variou
librari
supplement
tabl
supplement
tabl
interest
observ
virtual
screen
variou
estradiol
analog
score
well
eg
estradiol
valer
fit
valu
previous
estradiol
suggest
activ
ebov
pseudotyp
assay
vitro
addit
dibucain
also
retriev
fit
valu
also
activ
ebov
pseudotyp
assay
amodiaquin
chloroquin
clomiphen
toremifen
use
posit
control
futur
screen
origin
complet
set
fda
approv
compound
screen
public
access
difficult
compar
hit
rate
versu
compound
test
date
nine
receptorligand
pharmacophor
creat
consist
three
four
hydrophob
featur
one
two
hydrogen
bond
featur
tabl
eight
pharmacophor
also
neg
ioniz
featur
suggest
receptorligand
base
approach
result
gener
similar
across
nine
structur
like
indic
similar
bind
mode
import
featur
interf
gener
hydrophob
pocket
proteinprotein
interact
redock
ligand
protein
result
rmsd
gener
indic
difficulti
predict
orient
compound
bind
rel
hydrophob
shallow
pocket
figur
molecul
rank
th
pose
libdock
score
figur
higher
score
better
four
fda
approv
drug
dock
structur
compound
dock
similarli
overlap
cocryst
ligand
figur
amodiaquin
chloroquin
higher
libdock
score
ligand
clomiphen
toremifen
libdock
score
less
four
fda
approv
drug
bound
similarli
pyrrolidinon
ligand
pocket
form
residu
subdomain
highlight
propos
energet
favor
interact
antimalari
candid
binder
score
favor
previous
publish
studi
suggest
mutat
result
nearcomplet
loss
bind
activ
previou
experi
common
featur
quantit
pharmacophor
model
demonstr
valu
predict
novel
activ
collect
fda
approv
drug
candid
predict
activ
may
assess
fit
valu
pharmacophor
model
score
use
priorit
compound
eventu
test
current
studi
hypothes
two
differ
class
compound
show
activ
ebov
vitro
vivo
may
share
common
pharmacophor
construct
pharmacophor
figur
indic
four
hydrophob
featur
hydrogen
bond
acceptor
featur
pharmacophor
ad
van
der
waal
surfac
limit
number
hit
retriev
use
screen
score
fda
drug
small
databas
identifi
structur
futur
evalu
vitro
test
supplement
tabl
supplement
tabl
compound
estradiol
dibucain
previous
describ
activ
vitro
ebov
assay
suggest
pharmacophor
could
retriev
structur
divers
class
known
hit
recent
identifi
cocryst
structur
ebov
protein
use
deriv
receptorligand
pharmacophor
nine
receptorligand
pharmacophor
suggest
import
hydrophob
hydrogen
bond
neg
ioniz
interact
interfer
proteinprotein
interact
tabl
eight
nine
pharmacophor
one
hydrogen
bond
acceptor
featur
pharmacophor
grossli
similar
ligand
base
pharmacophor
deriv
four
fda
approv
drug
inhibit
ebov
type
model
multipl
hydrophob
featur
least
one
hydrogen
bond
acceptor
dock
antimalari
serm
repres
structur
compound
found
overlap
xray
ligand
differ
extent
amodiaquin
chloroquin
libdock
score
greater
higher
redock
xray
ligand
indic
may
potenti
target
two
distinct
class
compound
howev
import
point
compar
dock
protein
ebov
could
also
possibl
molecul
activ
elsewher
well
via
mechan
specif
bind
protein
may
prefer
target
antimalari
serm
predict
bind
well
xray
ligand
use
dock
score
method
may
produc
differ
pose
predict
bind
affin
could
interest
studi
combin
promis
efficaci
chloroquin
ec
amodiaquin
ec
versu
ebov
avail
like
low
cost
priorit
laboratori
explor
mechanist
studi
possibl
protein
also
pursu
may
enlighten
observ
compound
also
report
activ
virus
exampl
chloroquin
activ
human
coronaviru
vitro
infect
mice
well
sar
vitro
amodiaquin
also
inhibit
dengu
viru
replic
infect
vitro
summari
studi
built
previou
public
identifi
four
fda
approv
compound
activ
differ
strain
ebov
pharmacophor
model
serm
aminoquinolin
suggest
compound
share
multipl
chemic
featur
base
overlap
four
hydrophob
featur
hydrogen
bond
acceptor
figur
may
common
mechan
target
suggest
may
like
target
base
overlap
receptorbas
pharmacophor
dock
crystal
structur
amodiaquin
chloroquin
score
particularli
well
term
dock
case
could
provid
mean
follow
small
molecul
analog
andor
addit
fda
approv
drug
could
target
proteinprotein
interact
tuberculosisfocus
research
comput
approach
reposit
compound
embrac
essenti
comput
predict
interrog
rigor
experiment
studi
exampl
least
two
silico
dock
studi
screen
commerci
avail
compound
propos
dock
fda
approv
drug
could
also
viabl
first
step
identifi
potenti
compound
could
use
activ
seek
collabor
experi
ebov
assay
enabl
translat
studi
believ
comput
inspir
approach
may
applic
known
infecti
pathogen
current
treatment
virus
relat
ebola
ultim
need
abl
leverag
approach
provid
antivir
futur
pathogen
dataset
pharmacophor
receptor
ligand
model
dock
data
fdaapprov
drug
inhibit
ebola
viru
ligandbas
pharmacophor
previous
made
avail
http
follow
pdb
structur
use
studi
model
advic
pleas
contact
sean
ekin
ekinssean
yahoocom
